UGP2 and diabetes mellitus: Common bottlenecks include: first, the need to confirm their long-term efficacy and safety in the context of chronic metabolic diseases such as diabetes, which differs significantly from acute injury models; second, the precise inhibition of the macrophage-specific UDPG-P2Y14R axis in the diabetic state by these compounds requires validation in disease models.